Lataa...
NPY(1)R-targeted peptide-mediated delivery of a dual PPARα/γ agonist to adipocytes enhances adipogenesis and prevents diabetes progression
OBJECTIVE: PPARα/γ dual agonists have been in clinical development for the treatment of metabolic diseases including type 2 diabetes and dyslipidemia. However, severe adverse side effects led to complications in clinical trials. As most of the beneficial effects rely on the compound activity in adip...
Tallennettuna:
| Julkaisussa: | Mol Metab |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Elsevier
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6931124/ https://ncbi.nlm.nih.gov/pubmed/31918918 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molmet.2019.11.009 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|